LSE:GSKPharmaceuticals
GSK’s Bepirovirsen Data Puts Hepatitis B Cure And Growth In Focus
GSK (LSE:GSK) and partner Chia Tai Tianqing reported positive Phase III results for hepatitis B drug bepirovirsen.
Data were published in the New England Journal of Medicine and presented at a major international liver conference.
The trials showed meaningful rates of functional cure in chronic hepatitis B, a setting where most patients currently need lifelong treatment.
Regulatory reviews are underway in China, the US, Europe, and Japan, with a decision in China expected in 2027.
For GSK,...